Key Outcome of HCV Trial: BIT225 Was Safe and Well-Tolerated
Share
Follow Us
The Editors at Hepatitis Central
March 18, 2016
Find out why BIT225 might potentially be used in combination with new Hepatitis C drugs to help shorten treatment times and improve treatment outcomes.
Biotron Phase 2 Hepatitis C Trial Success
March 17, 2016
PRNewswire — Biotron Limited (ASX: BIT) confirms positive outcomes from its Phase 2 study of its first-in-class antiviral drug BIT225.
The trial was designed to assess the safety and antiviral activity of three month’s dosing of BIT225 in patients infected with Hepatitis C virus (HCV). In addition, the trial provided key information on a new capsule form of BIT225, information that is critical for determining dosage in further studies with the drug.
Continue reading this entire article:
http://www.prnewswire.com/news-releases/biotron-phase-2-hepatitis-c-trial-success-300237625.html
